Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
PURPOSE: The purpose of this study was to investigate whether positron emission tomography (PET) with the glucose analog [18 F]fluorodeoxyglucose (FDG) and the estrogen analog 16 alpha-[18 F]fluoroestradiol-17 beta (FES), performed before and after treatment with tamoxifen, could be used to detect hormone-induced changes in tumor metabolism (metabolic flare) and changes in available levels of estrogen receptor (ER). In addition, we investigated whether these PET findings would predict hormonally responsive breast cancer. PATIENTS AND METHODS: Forty women with biopsy-proved advanced ER-positive (ER+) breast cancer underwent PET with FDG and FES before and 7 to 10 days after initiation of tamoxifen therapy; 70 lesions were evaluated. Tumor FDG and FES uptake were assessed semiquantitatively by the standardized uptake value (SUV) method. The PET results were correlated with response to hormonal therapy. RESULTS: In the responders, the tumor FDG uptake increased after tamoxifen by 28.4% ± 23.3% (mean ± SD); only five of these patients had evidence of a clinical flare reaction. In nonresponders, there was no significant change in tumor FDG uptake from baseline (mean change, 10.1% ± 16.2%; P = .0002 v responders). Lesions of responders had higher baseline FES uptake (SUV, 4.3 ± 2.4) than those of nonresponders (SUV, 1.8 ± 1.3; P = .0007). All patients had evidence of blockade of the tumor ERs 7 to 10 days after initiation of tamoxifen therapy; however, the degree of ER blockade was greater in the responders (mean percentage decrease, 54.8% ± 14.2%) than in the nonresponders (mean percentage decrease, 19.4% ± 17.3%; P = .0003). CONCLUSION: The functional status of tumor ERs can be characterized in vivo by PET with FDG and FES. The results of PET are predictive of responsiveness to tamoxifen therapy in patients with advanced ER+ breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schelling, M., Avril, N., Nährig, J., Kuhn, W., Römer, W., Sattler, D., Werner, M., Dose, J., Jänicke, F., Graeff, H., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1689 · Cited by 522
Breast cancer: PET imaging of estrogen receptors.
Mintun, M. A., Welch, M. J., Siegel, B. A., Mathias, C. J., Brodack, J. W., McGuire, A. H., & Katzenellenbogen, J. A. (1988) · Radiology · doi:10.1148/radiology.169.1.3262228 · Cited by 416
Self-citationSmith, I. C., Welch, A. E., Hutcheon, A. W., Miller, I. D., Payne, S., Chilcott, F., Waikar, S., Whitaker, T., Ah-See, A. K., Eremin, O., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1676 · Cited by 406
Dehdashti, F., Flanagan, F. L., Mortimer, J. E., Katzenellenbogen, J. A., Welch, M. J., & Siegel, B. A. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050359 · Cited by 290
Self-citationLung tumor imaging by positron emission tomography using C-11 L-methionine.
Kubota, K., Matsuzawa, T., Ito, M., Ito, K., Fujiwara, T., Abe, Y., Yoshioka, S., Fukuda, H., Hatazawa, J., & Iwata, R. (1985) · PubMed · Cited by 163
Vollenweider-Zerargui, L., Barrelet, L., Wong, Y., Lemarchand-Béraud, T., & Gómez, F. (1986) · Cancer · Cited by 150
Toorongian, S. A., Mulholland, G. K., Jewett, D. M., Bachelor, M. A., & Kilbourn, M. R. (1990) · International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology · doi:10.1016/0883-2897(90)90052-3 · Cited by 148
Reddel, R. R., & Sutherland, R. L. (1984) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(84)90062-2 · Cited by 125
Alanko, A., Heinonen, E., Scheinin, T. M., Tolppanen, E., & Vihko, R. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7<1696::aid-cncr2820560738>3.0.co;2-n · Cited by 110
Flanagan, F. L., Dehdashti, F., & Siegel, B. A. (1998) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(98)80034-2 · Cited by 97
Self-citationAge-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer.
Guadagnoli, E., Shapiro, C., Gurwitz, J. H., Silliman, R. A., Weeks, J. C., Borbas, C., & Soumerai, S. B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2338 · Cited by 77
A Tour of UnifyPow: A SAS Module/Macro for Sample-Size Analysis
OʼBrien, R. G. (1998) · Cited by 52
Burns, R. B., Freund, K. M., Moskowitz, M. A., Kasten, L. E., Feldman, H. A., & McKinlay, J. B. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00156-3 · Cited by 27
Cited by
Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Self-citationBone Imaging in Metastatic Breast Cancer
Hamaoka, T., Madewell, J. E., Podoloff, D. A., Hortobagyi, G. N., & Ueno, N. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.181 · Cited by 656
EANM/SNMMI Guideline for18F-FDG Use in Inflammation and Infection
Jamar, F., Buscombe, J., Chiti, A., Christian, P. E., Delbeke, D., Donohoe, K. J., Israel, O., Martin-Comin, J., & Signore, A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112524 · Cited by 577
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Metadata
- Authors
- Mortimer, J. E., Dehdashti, F., Siegel, B. A., Trinkaus, K., Katzenellenbogen, J. A., & Welch, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-06-01
- Volume
- 19
- Issue
- 11
- Pages
- 2797-2803
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1809083310
- Cited by
- 410
- References
- 13
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.